Core Viewpoint - Heng Rui Medicine (01276) saw a significant stock price increase of over 7%, reaching a new high of 91 HKD, following the acceptance of its drug application by the National Medical Products Administration [1] Group 1: Company Developments - Heng Rui Medicine's subsidiary received an acceptance notice for the marketing license application of SHR-A1811, a drug for treating HER2-positive breast cancer patients [1] - The drug has been included in the priority review process, indicating its potential significance in the market [1] Group 2: Financial Performance - In the first half of 2025, Heng Rui Medicine achieved a net profit attributable to shareholders of 4.45 billion CNY, representing a year-on-year growth of 29.67% [1] - The net profit for the second quarter of 2025 was reported at 2.58 billion CNY, with a year-on-year increase of 24.88% [1] Group 3: Future Outlook - The company is expected to see rapid growth in its innovative drugs, with international contributions to profits continuing to rise [1] - Since the beginning of 2025, the company has secured 700 million USD in upfront licensing fees, indicating strong overseas revenue growth [1] - With a rich pipeline of products, the company is projected to maintain high-speed growth in innovative drugs over the next three years [1]